PMC:7156291 / 13761-17982 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T36","span":{"begin":1059,"end":1063},"obj":"Body_part"},{"id":"T37","span":{"begin":1123,"end":1127},"obj":"Body_part"},{"id":"T38","span":{"begin":2183,"end":2187},"obj":"Body_part"},{"id":"T39","span":{"begin":2912,"end":2916},"obj":"Body_part"},{"id":"T40","span":{"begin":2972,"end":2987},"obj":"Body_part"},{"id":"T41","span":{"begin":3093,"end":3098},"obj":"Body_part"},{"id":"T42","span":{"begin":3126,"end":3141},"obj":"Body_part"},{"id":"T43","span":{"begin":3271,"end":3286},"obj":"Body_part"},{"id":"T44","span":{"begin":3421,"end":3436},"obj":"Body_part"},{"id":"T45","span":{"begin":3658,"end":3673},"obj":"Body_part"},{"id":"T46","span":{"begin":3776,"end":3792},"obj":"Body_part"}],"attributes":[{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma25056"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma7371"},{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma7371"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma7371"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma7371"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma7371"},{"id":"A46","pred":"fma_id","subj":"T46","obj":"http://purl.org/sig/ont/fma/fma7371"}],"text":"Evolution of CT findings in patients with COVID-19\nThe initial CTs of 4 out of 88 (4.5%) patients were negative. Two of these four patients had their baseline CT during days 1–3, one during days 4–7, and one during days 8–10 of disease. Subsequently, CT images of one patient remained negative even during days 8–10, and other patients developed CT abnormalities.\nThere were significant differences between the time interval groups after disease onset in proportions of patients with both GGO and consolidation (χ2 = 22.2, p \u003c 0.01) and the combination of GGO, consolidation, and linear opacities (χ2 = 21.5, p \u003c 0.01) (Table 2). A proportion of patients with GGO and consolidation presented a decreasing trend during the 21 days after disease onset (y = 0.48–0.09x, p \u003c 0.01), while a proportion of patient with all three findings including ground glass opacities, consolidation, and linear opacities presented an increasing trend (y = 0.12–0.11x, p \u003c 0.01). No significant difference was found in the proportions of patients with other CT findings or total lung severity score.\nTable 2 Evolution of CT findings and total lung severity scores of patients with COVID-19 within 21 days after disease onset\nCharacteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –\nNumbers in parentheses are percentages\nn number of patients, GGO ground glass opacities\nNone of the patients had pleural effusions or intrathoracic lymphadenopathy during the follow-up period. Some of the patients had cavitation on CT, but these are thought to represent pre-existing conditions as none of the patients in the study cohort developed cavitation on follow-up CT.\nFigures 3 and 4 show the evolution of CT findings of two patients with COVID-19 pneumonia.\nFig. 3 A 54-year-old woman with exposure to a COVID-infected patient presented with fever, cough, and low back pain for 2 days and remains hospitalized. a–c CT shows left lower lobe GGO on day 2. The total severity score is 1. d–f CT on day 7 shows a significant increase in GGO in both lungs. The severity score of the left lower lobe is 2. The total severity score is 5. g–i CT on day 9 shows bilateral GGO and subpleural consolidation. The severity score of the left lower lobe is 3. The total severity score is 9. j–l CT on day 11 shows diffuse GGO and linear opacities (thick arrow). The severity score of the left lower lobe is 4. The total severity score is 12\nFig. 4 A 24-year-old man with exposure to a COVID-infected patient presented with fever and cough for 1 day and remains hospitalized currently. a–e CT scan shows GGO in the subpleural left lower lobe on day 1 (thick arrow). The overall total severity score is 1. f–j CT on day 4 shows enlarging GGO in left lower lobes (thick arrow). The overall total severity score is 3. k–o CT on day 8 shows increased GGO in bilateral lower lobes. The total severity score was 5. p–t CT obtained on day 11 shows bilateral ground glass opacities and linear opacities (thick arrow). The overall total severity score was 7. u–y CT obtained on day 15 shows improvement of bilateral lower lobe GGO and atoll sign (thick arrow). The overall total severity score is 5"}

LitCovid-PD-UBERON

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T40","span":{"begin":42,"end":50},"obj":"Disease"},{"id":"T41","span":{"begin":1161,"end":1169},"obj":"Disease"},{"id":"T42","span":{"begin":2065,"end":2080},"obj":"Disease"},{"id":"T43","span":{"begin":2486,"end":2501},"obj":"Disease"},{"id":"T44","span":{"begin":2786,"end":2794},"obj":"Disease"},{"id":"T45","span":{"begin":2795,"end":2804},"obj":"Disease"}],"attributes":[{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Evolution of CT findings in patients with COVID-19\nThe initial CTs of 4 out of 88 (4.5%) patients were negative. Two of these four patients had their baseline CT during days 1–3, one during days 4–7, and one during days 8–10 of disease. Subsequently, CT images of one patient remained negative even during days 8–10, and other patients developed CT abnormalities.\nThere were significant differences between the time interval groups after disease onset in proportions of patients with both GGO and consolidation (χ2 = 22.2, p \u003c 0.01) and the combination of GGO, consolidation, and linear opacities (χ2 = 21.5, p \u003c 0.01) (Table 2). A proportion of patients with GGO and consolidation presented a decreasing trend during the 21 days after disease onset (y = 0.48–0.09x, p \u003c 0.01), while a proportion of patient with all three findings including ground glass opacities, consolidation, and linear opacities presented an increasing trend (y = 0.12–0.11x, p \u003c 0.01). No significant difference was found in the proportions of patients with other CT findings or total lung severity score.\nTable 2 Evolution of CT findings and total lung severity scores of patients with COVID-19 within 21 days after disease onset\nCharacteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –\nNumbers in parentheses are percentages\nn number of patients, GGO ground glass opacities\nNone of the patients had pleural effusions or intrathoracic lymphadenopathy during the follow-up period. Some of the patients had cavitation on CT, but these are thought to represent pre-existing conditions as none of the patients in the study cohort developed cavitation on follow-up CT.\nFigures 3 and 4 show the evolution of CT findings of two patients with COVID-19 pneumonia.\nFig. 3 A 54-year-old woman with exposure to a COVID-infected patient presented with fever, cough, and low back pain for 2 days and remains hospitalized. a–c CT shows left lower lobe GGO on day 2. The total severity score is 1. d–f CT on day 7 shows a significant increase in GGO in both lungs. The severity score of the left lower lobe is 2. The total severity score is 5. g–i CT on day 9 shows bilateral GGO and subpleural consolidation. The severity score of the left lower lobe is 3. The total severity score is 9. j–l CT on day 11 shows diffuse GGO and linear opacities (thick arrow). The severity score of the left lower lobe is 4. The total severity score is 12\nFig. 4 A 24-year-old man with exposure to a COVID-infected patient presented with fever and cough for 1 day and remains hospitalized currently. a–e CT scan shows GGO in the subpleural left lower lobe on day 1 (thick arrow). The overall total severity score is 1. f–j CT on day 4 shows enlarging GGO in left lower lobes (thick arrow). The overall total severity score is 3. k–o CT on day 8 shows increased GGO in bilateral lower lobes. The total severity score was 5. p–t CT obtained on day 11 shows bilateral ground glass opacities and linear opacities (thick arrow). The overall total severity score was 7. u–y CT obtained on day 15 shows improvement of bilateral lower lobe GGO and atoll sign (thick arrow). The overall total severity score is 5"}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29","span":{"begin":2212,"end":2214},"obj":"Chemical"}],"attributes":[{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"}],"text":"Evolution of CT findings in patients with COVID-19\nThe initial CTs of 4 out of 88 (4.5%) patients were negative. Two of these four patients had their baseline CT during days 1–3, one during days 4–7, and one during days 8–10 of disease. Subsequently, CT images of one patient remained negative even during days 8–10, and other patients developed CT abnormalities.\nThere were significant differences between the time interval groups after disease onset in proportions of patients with both GGO and consolidation (χ2 = 22.2, p \u003c 0.01) and the combination of GGO, consolidation, and linear opacities (χ2 = 21.5, p \u003c 0.01) (Table 2). A proportion of patients with GGO and consolidation presented a decreasing trend during the 21 days after disease onset (y = 0.48–0.09x, p \u003c 0.01), while a proportion of patient with all three findings including ground glass opacities, consolidation, and linear opacities presented an increasing trend (y = 0.12–0.11x, p \u003c 0.01). No significant difference was found in the proportions of patients with other CT findings or total lung severity score.\nTable 2 Evolution of CT findings and total lung severity scores of patients with COVID-19 within 21 days after disease onset\nCharacteristic Time after disease onset χ2 p value\nDays 0–3 (n = 37) Days 4–7 (n = 69) Days 8–10 (n = 53) Days 11–14 (n = 49) Days 15–21 (n = 25)\nPulmonary opacities\n GGO only 8 (21.6) 13 (18.8) 7 (13.2) 4 (8.2) 1 (4.0) 6.6 0.16\n GGO and consolidation 12 (32.4) 26 (37.7) 8 (15.1) 5 (10.1) 1 (4.0) 22.2 \u003c 0.01\n GGO and linear opacities 2 (5.4) 2 (2.9) 4 (7.5) 2 (4.1) 2 (8.0) 1.87 0.76\n Consolidation only 1 (2.8) 6 (8.7) 3 (5.7) 4 (8.2) 1 (4.0) 1.98 0.74\n Consolidation and linear opacities 0 (0) 2 (2.9) 4 (7.5) 4 (8.2) 3 (12.0) 6.0 0.19\n GGO, consolidation, and linear opacities 12 (32.4) 19 (27.5) 25 (47.2) 30 (61.2) 17 (68.0) 21.5 \u003c 0.01\n Negative CT 2 (5.4) 1 (1.5) 2 (3.8) 0 (0.0) 0 (0.0) 4.3 0.36\nOther findings\n Discrete pulmonary nodules 4 (10.8) 4 (5.8) 3 (5.7) 1 (2.0) 0 (0) 4.8 0.36\n Pleural effusion 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Lymphadenopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) – –\n Cavitation 3 (8.1) 3 (4.3) 1 (1.9) 2 (4.1) 1 (4.0) 2.1 0.72\nTotal lung severity score\n Mean ± SD 3.9 ± 2.7 4.8 ± 2.9 4.9 ± 2.8 5.3 ± 3.3 5.2 ± 2.8 – 0.29\n Median (range) 4 (0–10) 5 (0–12) 5 (0–11) 5 (1–13) 5 (1–11) – –\nNumbers in parentheses are percentages\nn number of patients, GGO ground glass opacities\nNone of the patients had pleural effusions or intrathoracic lymphadenopathy during the follow-up period. Some of the patients had cavitation on CT, but these are thought to represent pre-existing conditions as none of the patients in the study cohort developed cavitation on follow-up CT.\nFigures 3 and 4 show the evolution of CT findings of two patients with COVID-19 pneumonia.\nFig. 3 A 54-year-old woman with exposure to a COVID-infected patient presented with fever, cough, and low back pain for 2 days and remains hospitalized. a–c CT shows left lower lobe GGO on day 2. The total severity score is 1. d–f CT on day 7 shows a significant increase in GGO in both lungs. The severity score of the left lower lobe is 2. The total severity score is 5. g–i CT on day 9 shows bilateral GGO and subpleural consolidation. The severity score of the left lower lobe is 3. The total severity score is 9. j–l CT on day 11 shows diffuse GGO and linear opacities (thick arrow). The severity score of the left lower lobe is 4. The total severity score is 12\nFig. 4 A 24-year-old man with exposure to a COVID-infected patient presented with fever and cough for 1 day and remains hospitalized currently. a–e CT scan shows GGO in the subpleural left lower lobe on day 1 (thick arrow). The overall total severity score is 1. f–j CT on day 4 shows enlarging GGO in left lower lobes (thick arrow). The overall total severity score is 3. k–o CT on day 8 shows increased GGO in bilateral lower lobes. The total severity score was 5. p–t CT obtained on day 11 shows bilateral ground glass opacities and linear opacities (thick arrow). The overall total severity score was 7. u–y CT obtained on day 15 shows improvement of bilateral lower lobe GGO and atoll sign (thick arrow). The overall total severity score is 5"}

LitCovid-PD-HP

LitCovid-sentences

PMC:7156291 / 13761-17982 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7156291 / 13761-17982 JSON TXT